Previous Close | 12.70 |
Open | 13.48 |
Bid | 14.55 x 0 |
Ask | 14.65 x 0 |
Day's Range | 13.34 - 15.67 |
52 Week Range | 5.62 - 35.80 |
Volume | |
Avg. Volume | 274,281 |
Market Cap | 568.717M |
Beta (5Y Monthly) | 1.64 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.74 |
Earnings Date | Feb 19, 2025 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 20.00 |
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today the appointment of Olav Hellebø as CEO. Mr. Hellebø will assume the position on November 21, 2024.
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharma-ceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter and half year ended September 30, 2024, and provided a business update.